In a multicenter trial this spring, about 12% of atopic and IMHA‑prone dogs failed to seroconvert to an inactivated Leptospira bacterin by day 28, with elevated baseline IL‑10 and low CXCL13 suggesting impaired germinal center dynamics. Has anyone successfully mitigated this — e.g., by pre-screening with a minimal cytokine panel or shifting to a TLR7/8‑biased adjuvant for that phenotype — and did it translate to durable neutralizing titers rather than just transient boosts?
We switched to “size the largest brush that passes without blanching” — I chart by tooth ranges with TePe colors (e.g., 12–17 green, 22–27 orange), hand a wallet card, and snap a quick photo in the chart; it’s like shoe sizes. For very tight contacts or fixed retainers, I go PTFE tape or Superfloss with a threader and the pink 0.4 mm where it fits — are you using the TePe gauge or the CPS probe?
Quick example: we’ve been doing a small send‑out panel for “IL‑10/CXCL13” the week before; if IL‑10 is up we delay and recheck in 2–3 weeks instead of burning a dose, . When we can’t wait, priming the site with a TLR7/8 gel (resiquimod) and planning a third shot at day 42 pushed a few day‑28 non‑responders over the line. Caveat: the IL‑10 assays are finicky and the gel can sting, so not every owner is game.
We’ve had better luck adding a third priming dose at 6–8 weeks in these dogs and, when safe, pausing cyclosporine/oclacitinib for 48–72 h around the shot to cut IL‑10 headwinds. In the few repeat non‑responders, a brand swap (different adjuvant) nudged titers up; small risk is atopic flare, so warn owners. WSAVA’s vaccination guidance is a decent backstop: Vaccination Guidelines - WSAVA @annika_dvm.
We push titer checks beyond ‘day 28’ to day 42–56; doesn’t rescue true poor responders.